

CURRICULUM VITAE

Antonia Mancuso was born in Catanzaro (Italy) on June 17th, 1992.

She graduated in Pharmacy (110/110 cum laude) at the University “Magna Græcia” of Catanzaro in 2018 discussing an experimental thesis in pharmaceutical technology, socioeconomics and legislation concerning the effects of ultradeformable vesicles, charged with idebenone and naproxen, for the treatment of inflammatory diseases.

In 2018 she gained the qualification as pharmacist profession practice and she started a PhD in Life Science (curriculum in Pharmaceutical Science) at the University “Magna Græcia” of Catanzaro. Her research interest is focused on the preparation, physico-chemical characterization, *in vivo* and *in vitro* studies on the toxicity and efficacy of new topical drug delivery systems for the treatment of skin diseases.

She is currently part of several national and international scientific societies, such as A.D.R.I.T.E.L.F., CRS Italy Chapter and SCI.

List of publications:

Cristiano, M.C., Froiio, F., Mancuso, A., Iannone, M., Fresta, M., Fiorito, S., Celia, C., Paolino, D. In vitro and in vivo trans-epidermal water loss evaluation following topical drug delivery systems application for pharmaceutical analysis. (2020) *Journal of Pharmaceutical and Biomedical Analysis*, 186, 113295.

Cristiano, M.C., Froiio, F., Mancuso, A., de Gaetano, F., Ventura, C.A., Fresta, M., Paolino, D. The Rheolaser Master™ and Kinexus rotational rheometer® to evaluate the influence of topical drug delivery systems on rheological features of topical poloxamer gel. (2020) *Molecules*, 25 (8), 1979.

Cristiano, M.C., Froiio, F., Spaccapelo, R., Mancuso, A., Nisticò, S.P., Udongo, B.P., Fresta, M., Paolino, D. Sulfuraphane-loaded ultradeformable vesicles as a potential natural nanomedicine for the treatment of skin cancer diseases. (2020) *Pharmaceutics*, 12 (1), 6.

Molinaro, R., Gagliardi, A., Mancuso, A., Donato, C., Soliman, M.E., Casettari, L., Paolino, D. Development and In Vivo Evaluation of Multidrug Ultradeformable Vesicles for the Treatment of Skin Inflammation. (2019) *Pharmaceutics*, 11 (12), 644.

